Clinical trials: Head and Neck Cancer Metastatic
Nasopharyngeal Carcinoma
TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
This study consists of two parts: Part 1 encompasses a safety lead - in phase and an expansion phase. In both phases, subjects with advanced nasopharyngeal carcinoma who have previously failed platinum - based chemotherapy and…
- Trial name
- NCT05563480
- Testing
- TQB2618 Injection, Pempulimab Injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection, TQB2618 injection; Penpulimab injection
- Where
- 5 sites in China
- Volunteers
- 47 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Head and Neck Carcinoma, Head and Neck Carcinoma of Unknown Primary
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
This clinical trial studies how well intensity modulated proton therapy (IMPT) or intensity modulated X-ray (radiation) therapy (IMRT) works after surgery in treating patients with head and neck cancer.
- Conditions
- Head and Neck Carcinoma, Head and Neck Carcinoma of Unknown Primary, Hypopharyngeal Carcinoma, Laryngeal Carcinoma
- Trial name
- NCT05075980
- Testing
- Cisplatin, Intensity-Modulated Proton Therapy, Quality-of-Life Assessment
- Where
- 9 sites in United States
- Volunteers
- 174 people
- Sponsor
- Mayo Clinic
Colorectal Cancer, Endometrial Cancer
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
RATIONALE: Vaccines made from a peptide may make the body build an immune response to kill tumor cells. Combining vaccine therapy with interleukin-2 and/or sargramostim may be a more effective treatment for solid tumors.
- Conditions
- Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Liver Cancer
- Trial name
- NCT00019331
- Testing
- aldesleukin, ras peptide cancer vaccine, sargramostim
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Oral Squamous Cell Carcinoma (OSCC)
Study Comparing Different Neck Treatment Approaches in Patients With Oral Cancer Without Visible Neck Spread
The goal of this clinical trial is to learn whether selective neck dissection involving lymph node levels I-III is as effective as selective neck dissection involving levels I-IV in treating adults with clinically node-negative…
- Trial name
- ExtentN0 (NCT07726199)
- Testing
- Selective Neck Dissection (Levels I-IV), Intervention : Selective Neck Dissection (Levels I-III)
- Where
- India
- Volunteers
- 267 people
- Sponsor
- Kolhapur Cancer Centre - Cancer Centers of America
Nasopharyngeal Carcinoma
Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA
This is a single-arm, multi-center, open-label, phase II trial to examine the efficacy of pembrolizumab for prolonging the one-year disease free survival in nasopharyngeal carcinoma patients with solely detectable EBV DNA after…
- Trial name
- NCT03544099
- Testing
- Pembrolizumab
- Where
- 8 sites in Taiwan
- Volunteers
- 2 people
- Sponsor
- National Health Research Institutes, Taiwan
Neoplasms, Head and Neck
Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck
This study is being conducted to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in adult subjects with squamous cell carcinoma of the head and neck (SCCHN).
- Trial name
- NCT00725764
- Testing
- GSK1363089 (foretinib)
- Where
- 11 sites in United States
- Volunteers
- 14 people
- Sponsor
- GlaxoSmithKline
Head and Neck Cancer
Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck
The purpose of this study is to determine if IMC-A12 alone or in combination with Cetuximab (Erbitux®) can increase the time prior to disease progression in participants with Squamous Cell Head and Neck Cancer who have had…
- Trial name
- NCT00617734
- Testing
- IMC-A12 (cixutumumab), cetuximab (Erbitux ®)
- Where
- 14 sites in United States
- Volunteers
- 97 people
- Sponsor
- Eli Lilly and Company
Salivary Gland Cancer
Androgen Deprivation Therapy in Advanced Salivary Gland Cancer
Salivary Gland (SG) Cancers are a rare and heterogeneous group of tumors, usually approached by multidisciplinary teams in high specialized centers. Until today no standard of care exists to treat these cancers.
- Trial name
- NCT01969578
- Testing
- bicalutamide + triptorelin, Cisplatin + Doxorubicin, Carboplatin + Paclitaxel
- Where
- 26 sites in Austria, Belgium and 6 more
- Volunteers
- 149 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Colorectal Cancer, Squamous Cell Head and Neck Cancer
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
The purpose of this study was to evaluate the safety and tolerability of escalating doses of the MM-121 plus cetuximab and the MM-121 plus cetuximab plus irinotecan combination.
- Conditions
- Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer
- Trial name
- NCT01451632
- Testing
- MM-121, Irinotecan, Cetuximab
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Merrimack Pharmaceuticals
Head and Neck Squamous Cell Carcinoma
SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma
This study is an open-label, multi-center, phase II study to evaluate the efficacy and safety of SYS6010 combined with immunotherapy in the recurrent or metastatic head and neck squamous cell carcinoma.
- Trial name
- NCT07254585
- Testing
- SYS6010 injection, Enlonstobart injection, Pembrolizumab injection
- Where
- China
- Volunteers
- 110 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Esophageal Squamous Cell Cancer, Elderly Patients
Sequential Paclitaxel Chemotherapy and Radiotherapy as 1st Line Treatment for Elderly Esophageal Squamous Cell Cancer
Elderly patients with metastatic esophageal squamous cell carcinomas have poor prognosis and majority of them were intolerable to combined chemotherapy in China.
- Trial name
- NCT02016287
- Testing
- Sequential chemotherapy （paclitaxel 80mg/m2 d1,d8) and radiotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shen Lin
Lung Cancer, Esophageal Cancer
Mithramycin for Lung, Esophagus, and Other Chest Cancers
Background: Mithramycin is a drug that was first tested as a cancer therapy in the 1960s. It acted against some forms of cancer, but was never accepted as a treatment.
- Conditions
- Lung Cancer, Esophageal Cancer, Mesothelioma, Gastrointestinal Neoplasms
- Trial name
- NCT01624090
- Testing
- Mithramycin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck
PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response
This is a randomized, open-label, 2-arm, controlled, phase 2, multi-center, estimation clinical trial of docetaxel and cisplatin combination chemotherapy with and without panitumumab in the first-line treatment of subjects with…
- Trial name
- NCT00454779
- Testing
- Cisplatin, Panitumumab, Docetaxel
- Where
- 114 sites in United States, Austria and 7 more
- Volunteers
- 113 people
- Sponsor
- Amgen
Head and Neck Cancer
Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2
This is a phase I study of second primary tumor prevention in early stage (stage I/II) patients diagnosed with squamous cell carcinoma of the head and neck (SCCHN).
- Trial name
- NCT00400374
- Testing
- Erlotinib, Celecoxib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Emory University
Head and Neck Cancer
BMS-247550 Plus Cisplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase I/II trial to study the effectiveness of combining BMS-247550 with cisplatin in treating patients who have metastatic or recurrent head and neck cancer.
- Trial name
- NCT00057850
- Testing
- cisplatin, ixabepilone
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
MGC018 With or Without MGA012 in Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of vobramitamab duocarmazine (MGC018) in patients with advanced solid tumors.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Melanoma, Advanced Solid Tumor, Adult
- Trial name
- NCT03729596
- Testing
- vobramitamab duocarmazine
- Where
- 21 sites in United States, Australia and 2 more
- Volunteers
- 143 people
- Sponsor
- MacroGenics
Laryngeal Cancer, Hypopharyngeal Cancer
The Role of MMPs in the CXCL12-Induced Invasion of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma
Investigate the role of MMPs in the CXCL12-induced invasion of laryngeal and hypopharyngeal squamous cell carcinoma
- Trial name
- NCT00302562
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma
GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients
The purpose of this study is to test the safety \& efficacy of combination drugs versus placebo to treat metastatic melanoma and head and neck squamous cell carcinoma.
- Trial name
- NCT04987996
- Testing
- GR-MD-02, Pembrolizumab
- Where
- United States
- Sponsor
- Providence Health & Services
HNSCC
Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC
Evaluate the safety and efficacy of eftilagimod alpha in combination with pembrolizumab against pembrolizumab alone in 1st line metastatic or recurrent HNSCC with programmed death-ligand 1 (PD-L1) positive (combined positive…
- Trial name
- TACTI-003 (NCT04811027)
- Testing
- eftilagimod alpha, pembrolizumab (KEYTRUDA®)
- Where
- 28 sites in United States, Australia and 7 more
- Volunteers
- 171 people
- Sponsor
- Immutep S.A.S.
Head and Neck Squamous Cell Carcinoma
A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This study is a open, multi-center phase II clinical study to explore the efficacy, safety and pharmacokinetic/pharmacodynamic characteristics of SI-B001+SI-B003 combined with platinum-based chemotherapy as first-line treatment…
- Trial name
- NCT06668961
- Testing
- SI-B001, SI-B003
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.